title: Synaptic pathology of Down syndrome.
abstract: Down syndrome is characterized by mild to moderate cognitive impairments that are caused by trisomy of chromosome 21. Several anatomical, behavioral, electrophysiological, and developmental abnormalities have been associated with Down syndrome. In this review, the current knowledge about the neurobiology of this disease and future perspectives of pharmacological treatments for this condition will be discussed.
authors.affiliation: Department of Psychiatry and Behavioral Sciences, Nancy Pritzker Laboratory, Stanford University School of Medicine, Palo Alto, CA, USA. cgarner@stanford.edu
authors.forename: Craig C
authors.initials: CC
authors.lastname: Garner
authors.forename: Daniel Z
authors.initials: DZ
authors.lastname: Wetmore
mesh_terms: D000818:Animals; D002891:Chromosomes, Human, Pair 21; D004195:Disease Models, Animal; D004314:Down Syndrome / Q000188:drug therapy / Q000235:genetics / Q000503:physiopathology*; D005786:Gene Expression Regulation; D006624:Hippocampus / Q000378:metabolism* / Q000503:physiopathology; D006801:Humans; D017774:Long-Term Potentiation; D051379:Mice; D008822:Mice, Transgenic; D058990:Molecular Targeted Therapy; D016202:N-Methylaspartate / Q000378:metabolism; D016194:Receptors, N-Methyl-D-Aspartate / Q000378:metabolism; D013569:Synapses / Q000235:genetics / Q000378:metabolism*; D009435:Synaptic Transmission / Q000235:genetics*; D014314:Trisomy / Q000235:genetics / Q000503:physiopathology
chemical_list: D016194:Receptors, N-Methyl-D-Aspartate; D016202:N-Methylaspartate